title: Prophylactic bisphosphonate treatment prevents bone fractures after liver transplantation.
abstract: A randomized controlled prospective open-label single center trial was performed. At the time of transplantation patients were randomly assigned to one of two treatment arms: The study group of 47 patients received zoledronic acid (ZOL, 8 infusions at 4 mg during the first 12 months after LT), calcium (1000 mg/d) and vitamin D (800 IE/d). The control group consisted of 49 patients who received calcium and vitamin D at same doses (CON). The incidence of bone fractures or death was predefined as the primary endpoint. Secondary endpoints included bone mineral density (BMD), serum biochemical markers of bone metabolism, parameters of trabecular bone histomorphometry and mineralization density distribution (BMDD). Patients were followed up for 24 months. Analysis was performed on an intention-to-treat basis. The primary endpoint fracture or death was reached in 26% of patients in the ZOL group and 46% in the CON group (p = 0.047, log rank test). Densitometry results were different between the groups at the femoral neck at 6 months after LT (mean+/-SD BMD ZOL: 0.80 +/- 0.19 g/cm2 vs. CON: 0.73 +/- 0.14 g/cm2, p = 0.036). Mixed linear models of biochemical bone markers showed less increase of osteocalcin in the ZOL group and histomorphometry and BMDD indicated a reduction in bone turnover. Prophylactic treatment with the bisphosphonate zoledronic acid reduces bone turnover and fractures after liver transplantation.
authors.affiliation: Division of Transplantation, Department of Surgery, Medical University of Vienna, Vienna, Austria. martin.bodingbauer@meduniwien.ac.at
authors.forename: M
authors.initials: M
authors.lastname: Bodingbauer
authors.forename: T
authors.initials: T
authors.lastname: Wekerle
authors.forename: B
authors.initials: B
authors.lastname: Pakrah
authors.forename: P
authors.initials: P
authors.lastname: Roschger
authors.forename: M
authors.initials: M
authors.lastname: Peck-Radosavljevic
authors.forename: G
authors.initials: G
authors.lastname: Silberhumer
authors.forename: S
authors.initials: S
authors.lastname: Grampp
authors.forename: S
authors.initials: S
authors.lastname: Rockenschaub
authors.forename: G
authors.initials: G
authors.lastname: Berlakovich
authors.forename: R
authors.initials: R
authors.lastname: Steininger
authors.forename: K
authors.initials: K
authors.lastname: Klaushofer
authors.forename: R
authors.initials: R
authors.lastname: Oberbauer
authors.forename: F
authors.initials: F
authors.lastname: Mühlbacher
mesh_terms: D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000453:epidemiology* / Q000517:prevention & control*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000009:adverse effects* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control*; D011446:Prospective Studies; D016019:Survival Analysis; D000077211:Zoledronic Acid
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid